[11/18/2014] MiNA Completes Exclusive License Agreement with University of California San Francisco.
LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that it has completed an exclusive license agreement with The Regents of the University of California relating to intellectual property rights developed by the Li lab at UC San Francisco (UCSF).

[12/1/2009] Vera Huang won a Prostate Cancer Training Award from Department of Defense (DOD) Prostate Cancer Research Program (PCRP). Congratulations!

[11/9/2009] Shangchen Ren from our lab won the BEST Presentation Award awarded by ARTP (French association for Prostate Cancer Research) at 8th World Congress in Urological Research organized by SBUR and ESUR and held in New Orleans between 11/5 and 11/8 for his work entitled "RNAa-mediated NKX3-1 activation inhibits growth of prostate cancer cells".

[9/24/2009] Today NIH announced the recipients of 42 NIH Director's Transformative R01 (TR01) awards. One was awarded to Dr. Long-Cheng Li and Hao Li to study the molecular mechanism and design rules of RNAa. Click here to read more about this project.

[5/1/2009] Our lab has just moved from UCSF Parnassus campus to its new home in the brand new Helen Diller Cancer Research Building at UCSF Mission Bay campus. Read more.

[8/4/2008] Alnylam Consolidates Intellectual Property for RNA Activation (RNAa)... Read more...